Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial
Iglesias J, Windecker S, Jüni P, Zwahlen M, Odutayo A, Valgimigli M, Eeckhout E, Losdat S, Stortecky S, Tapponnier M, Kaiser C, Weilenmann D, Moarof I, Kurz D, Roffi M, Heg D, Muller O, Pilgrim T. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. Lancet 2019; 394:1243-1253.
02.09.2019
Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial
02.09.2019
Lancet 2019; 394:1243-1253
Iglesias Juan F, Windecker Stephan, Jüni Peter, Zwahlen Marcel, Odutayo Ayodele, Valgimigli Marco, Eeckhout Eric, Losdat Sylvain, Stortecky Stefan, Tapponnier Maxime, Kaiser Christoph, Weilenmann Daniel, Moarof Igal, Kurz David J, Roffi Marco, Heg Dik, Muller Olivier, Pilgrim Thomas
Weiter